Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Gavreto
Pralsetinib is a targeted therapy used to treat a type of non-small cell lung cancer (NSCLC) called RET fusion-positive NSCLC. It's a kinase inhibitor, specifically targeting the rearranged during transfection (RET) protein, which plays a role in cancer growth. Pralsetinib works by blocking the activity of RET, thus hindering the proliferation of cancer cells.
Pralsetinib is used to treat adult patients with RET fusion-positive non-small cell lung cancer (NSCLC).
Outcome:
Decreased pralsetinib levels
Mechanism:
Increased metabolism
Outcome:
Increased pralsetinib levels
Mechanism:
Decreased metabolism
Outcome:
Decreased pralsetinib absorption
Mechanism:
Chelation/pH changes
Most likely new formulation: Extended-release formulation (Year 2025, 70% confidence)
Based on clinical trial data and increasing adoption, there is a high likelihood (>80%) of pralsetinib maintaining its approved status for RET fusion-positive NSCLC.
Kinase Inhibitor, Antineoplastic Agent
Aryl Carboxamide